TLSA Tiziana Life Sciences plc

2.08
0  0%
Previous Close 2.08
Open 2.04
52 Week Low 1.73
52 Week High 6.14
Market Cap $202,396,780
Shares 97,306,144
Float 25,352,639
Enterprise Value $123,461,561
Volume 199,614
Av. Daily Volume 479,085
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Foralumab
COVID-19
Phase 2
Phase 2
Phase 2 trial planned.
Milciclib and NEXAVAR (sorafenib)
Hepatocellular carcinoma (HCC)
Phase 2b
Phase 2b
Phase 2b trial planned.
Foralumab
Healthy volunteers
Phase 1
Phase 1
Phase 1 data released May 25, 2021. Significant immunomodulatory effects noted.
TZLS-501
Coronavirus COVID-19
Phase 1
Phase 1
Phase 1 trial planned.

Latest News

  1. THIS ANNOUNCEMENT IS FOR US ADS HOLDERS ONLY

    NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that its American Depository Shares ("ADS"), trading under the ticker TLSA, will begin trading ex-dividend on July 09, 2021.

    The non-cash dividend, in the form of an in-specie dividend of one Accustem Sciences Limited ADS (representing 2 ordinary shares in Accustem Sciences Limited) per TLSA ADS, is scheduled to be paid on July 14, 2021.

    Shareholders who purchased TLSA prior to the ex-dividend date are eligible for the non-cash dividend. 

    THIS ANNOUNCEMENT IS FOR US ADS HOLDERS ONLY

    NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that its American Depository Shares ("ADS"), trading under the ticker TLSA, will begin trading ex-dividend on July 09, 2021.

    The non-cash dividend, in the form of an in-specie dividend of one Accustem Sciences Limited ADS (representing 2 ordinary shares in Accustem Sciences Limited) per TLSA ADS, is scheduled to be paid on July 14, 2021.

    Shareholders who purchased TLSA prior to the ex-dividend date are eligible for the non-cash dividend. 

    Holders of TLSA should also refer to the notice published by JP Morgan, the ADR depositary bank which can be found at https://www.adr.com/drprofile/88875G101

    For further enquiries:

    United Kingdom:
     
    Tiziana Life Sciences plc

    Gabriele Cerrone,

    Chairman and founder
    +44 (0)20 7495 2379
    United States:

    Investors:

    Dave Gentry, CEO

    RedChip Companies Inc.

    1-800-RED-CHIP (733-2447)

    or

    407-491-4498

     



    Primary Logo

    View Full Article Hide Full Article
  2. LONDON and NEW YORK, July 02, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that the Forms 20-F and F-6 filed by Accustem Sciences Limited with the SEC have been declared effective, enabling the completion of the in specie distribution and spin out of Accustem Sciences Limited. These documents together can be found at www.accustem.com

    Times and dates for holders of Tiziana ordinary shares (traded on the London Stock Exchange)

    The timetable for the holders of Tiziana ordinary shares (traded on the London Stock Exchange) held in CREST and Certificated…

    LONDON and NEW YORK, July 02, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that the Forms 20-F and F-6 filed by Accustem Sciences Limited with the SEC have been declared effective, enabling the completion of the in specie distribution and spin out of Accustem Sciences Limited. These documents together can be found at www.accustem.com

    Times and dates for holders of Tiziana ordinary shares (traded on the London Stock Exchange)

    The timetable for the holders of Tiziana ordinary shares (traded on the London Stock Exchange) held in CREST and Certificated form is as follows:

    Demerger Record Time: 7:00 a.m. on 30 October 2020
      
    Ex-entitlement date for Accustem Shares: 2 November 2020
      
    CREST accounts credited with Accustem Shares:8 July 2021*
      
    Certificates for Accustem Shares for those shareholders

    holding their Tiziana Life Sciences plc in certificated form:
    by 18 July 2021
      
    * replacing allocation placeholders currently showing

    Times and dates for holders of Tiziana ADSs (traded on the US Nasdaq Market)

    The timetable for the holders of Tiziana ADSs (traded on the Nasdaq market) are subject to different corporate action timings and holders of the ADRs should also refer to the notice published today by JP Morgan, the ADR depositary bank which can be found at https://www.adr.com/drprofile/88875G101

    Announcement Tiziana CUSIP: 88875G101

    Corporate Action Type:Spin Off with DR Distribution
      
    Spin Off Issuer Name:Accustem Sciences Limited
      
    Spin Off DR CUSIP: 00442Y101
      
    DR Distribution Rate:1 new Accustem DR(s) issued for every 1 existing Tiziana DR held on DR Record Date
      
    Tax Withholding Rate: n/a
      
    DR Record Date:November 6, 2020
      
    DR Payment Date:July 14, 2021
      
    DR Issuance and Cancellation Books close Date: October 28, 2020
      
    DR Issuance and Cancellation Books reopen Date: July 19, 2021
      
    Fees: Issuance fee: $nil per DR issued

    The Issuer has announced a Spin Off Distribution in the local market. Existing Tiziana DRs will continue to be valid and will not have to be exchanged for new DRs.

    For further enquiries:

    United Kingdom:
     
    Tiziana Life Sciences plc

    Gabriele Cerrone,

    Chairman and founder
    +44 (0)20 7495 2379
    United States:

    Investors:

    Dave Gentry, CEO

    RedChip Companies Inc.

    1-800-RED-CHIP (733-2447)

    or

    407-491-4498

     


    Primary Logo

    View Full Article Hide Full Article
  3. NEW YORK and LONDON, June 30, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA, LSE: TILS))), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces an interview with the Chairman of its' Scientific Advisory Board and Professor of Neurology at Harvard Medical School, Dr Howard Weiner is to air on Bloomberg Markets with Matt Miller and Amanda Lang today at 1.50pm ET/6.50pm BST.

    About Tiziana Life Sciences

    Tiziana Life Sciences plc (NASDAQ:TLSA, LSE: TILS))) is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib (a CDK inhibitor being developed…

    NEW YORK and LONDON, June 30, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA, LSE: TILS))), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces an interview with the Chairman of its' Scientific Advisory Board and Professor of Neurology at Harvard Medical School, Dr Howard Weiner is to air on Bloomberg Markets with Matt Miller and Amanda Lang today at 1.50pm ET/6.50pm BST.

    About Tiziana Life Sciences

    Tiziana Life Sciences plc (NASDAQ:TLSA, LSE: TILS))) is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib (a CDK inhibitor being developed in oncology), the Company is also developing Foralumab in COVID-19, multiple sclerosis, and Crohn's Disease. Foralumab is the only second generation fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammatory pulmonary diseases.

    Forward-Looking Statements

    Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

    For further enquiries:

    United Kingdom:

    Tiziana Life Sciences plc

    Gabriele Cerrone, Chairman and founder

    +44 (0)20 7495 2379

    United States:

    Investors:

    Dave Gentry, CEO

    RedChip Companies Inc.

    407-491-4498



    Primary Logo

    View Full Article Hide Full Article
  4. LONDON, June 25, 2021 (GLOBE NEWSWIRE) -- At the Annual General Meeting of the Company held at 10.00 a.m. on 25 June 2021, all of the resolutions were duly passed.

    The results of the proxy voting will be available shortly on the Company's website, https://ir.tizianalifesciences.com/shareholder-services/annual-general-meeting.

    The Company also confirms that it has re-activated its strategic plan to redomicile to Bermuda; shareholders will receive further information in due course.

    The person who arranged for the release of this announcement was Keeren Shah, Chief Financial Officer.

    THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,

    LONDON, June 25, 2021 (GLOBE NEWSWIRE) -- At the Annual General Meeting of the Company held at 10.00 a.m. on 25 June 2021, all of the resolutions were duly passed.

    The results of the proxy voting will be available shortly on the Company's website, https://ir.tizianalifesciences.com/shareholder-services/annual-general-meeting.

    The Company also confirms that it has re-activated its strategic plan to redomicile to Bermuda; shareholders will receive further information in due course.

    The person who arranged for the release of this announcement was Keeren Shah, Chief Financial Officer.

    THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

    About Tiziana Life Sciences



    Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib (a CDK inhibitor being developed in oncology), the Company is also developing Foralumab in COVID-19, multiple sclerosis, and Crohns Disease. Foralumab is the only second generation fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammatory pulmonary diseases.     

    For further enquiries:

    United Kingdom: 
     
    Tiziana Life Sciences plc

    Gabriele Cerrone, Chairman and founder
    +44 (0)20 7495 2379


    United States:


    Investors:

    Dave Gentry, CEO

    RedChip Companies Inc.

    1-800-RED-CHIP (733-2447)

    or

    407-491-4498

     


    Primary Logo

    View Full Article Hide Full Article
  5. NEW YORK and LONDON, June 23, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA, LSE: TILS))), ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, announces that it has signed an agreement with FHI Clinical, a global clinical contract research organization (CRO), to conduct a Phase 2 Proof-of-concept study in Brazil to evaluate the safety, tolerability and efficacy of intranasal Foralumab in hospitalized patients with severe coronavirus disease 2019 (COVID-19) and pulmonary inflammation.

    A subsidiary of FHI 360, FHI Clinical specializes in the clinical development of drugs for infectious diseases (https://www.fhiclinical.com

    NEW YORK and LONDON, June 23, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA, LSE: TILS))), ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, announces that it has signed an agreement with FHI Clinical, a global clinical contract research organization (CRO), to conduct a Phase 2 Proof-of-concept study in Brazil to evaluate the safety, tolerability and efficacy of intranasal Foralumab in hospitalized patients with severe coronavirus disease 2019 (COVID-19) and pulmonary inflammation.

    A subsidiary of FHI 360, FHI Clinical specializes in the clinical development of drugs for infectious diseases (https://www.fhiclinical.com). The company's involvement with COVID-19 includes Phase 1 to Phase 3 clinical trials for vaccines and therapeutics, as well as observational studies to collect data about the characteristics and course of infection. With experience conducting related studies across 16 countries and 43 states in the United States, FHI Clinical has a large network of clinical sites throughout the world to expedite COVID-19 trials.

    In this clinical trial, Foralumab will be delivered intranasally through a metered-dose nasal atomization device. Nasal administration of Foralumab is a highly innovative approach to treat patients with autoimmune diseases where the immune system may be dysregulated. Several studies have suggested that there is dysregulation in the immune system of patients with COVID-19.

    This randomized, placebo-controlled, double-blind, proof-of-concept study is designed to expand on the preliminary findings of safety, tolerability and efficacy of intranasal administration of Foralumab observed in mild to moderate non-hospitalized COVID-19 patients (https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-life-sci-plc-positive-data-nasal-administration). Thus, this study will examine attenuation of pulmonary pathology in hospitalized patients with severe COVID-19. Up to seven sites in Brazil will be engaged to conduct this study. Eighty hospitalized patients with severe COVID-19 and evidence of pulmonary involvement on a computed tomography (CT) scan at screening will be enrolled. Patients will be randomized 1:1 to receive intranasal Foralumab 100 µg. Additionally, the study will also evaluate the effect of Foralumab on resolution of symptoms by chest CT, inflammatory biomarkers, T-cell subpopulations, safety and mucosal inflammatory response following 14 days of intranasal administration.

    "Our experience is uniquely suited to the needs of this Phase 2 study as we are able to pull from past outbreak experience, including rapid study start-up in research-naïve areas to leveraging existing global research networks and contributing to local health systems," said Ted FitzGerald, FHI Clinical President and CEO. "We excel at addressing the complex aspects of infectious disease trials that require thorough planning and contingency planning."

    "We are pleased to move forward with FHI Clinical on our next COVID-19 trial. After a successful proof-of-mechanism trial in mild to moderate COVID-19 outpatients with intranasal Foralumab earlier this year, the next step is to test it in more severe hospitalized patients with pulmonary inflammation," said Dr. Neil Graham, Chief Medical Officer at Tiziana Life Sciences.

    The person who arranged for the release of this announcement on behalf of the Company was Dr. Kunwar Shailubhai, Chief Executive Officer and Chief Scientific Officer of the Company.

    About Foralumab

    Foralumab (formerly NI-0401), the only entirely human anti-CD3 mAb, shows reduced release of cytokines after IV administration in patients with Crohn's disease with decreases in the classic side effects of cytokine release syndrome and improves the overall safety profile of Foralumab. In a humanized mouse model (NOD/SCID IL2γc-/-), it was shown that whilst targeting the T cell receptor, orally administered Foralumab modulates immune responses of the T cells, enhances regulatory T-cells (Tregs) and thus provides therapeutic benefit in treating inflammatory and autoimmune diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy (Ogura M. et al., 2017). Based on animal studies, the nasal and oral administration of Foralumab offers the potential for the immunotherapy of autoimmune and inflammatory diseases in a safe manner by the induction of Tregs.



    About Tiziana Life Sciences

    Tiziana Life Sciences plc (NASDAQ:TLSA, LSE: TILS))) is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib (a CDK inhibitor being developed in oncology), the Company is also developing Foralumab in COVID-19, multiple sclerosis, and Crohns Disease. Foralumab is the only second generation fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammatory pulmonary diseases.

    Forward-Looking Statements

    Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

    For further enquiries:

    United Kingdom:        

    Tiziana Life Sciences plc

    Gabriele Cerrone, Chairman and founder
    +44 (0)20 7495 2379
      
    United States:

    Investors:

    Dave Gentry, CEO

    RedChip Companies Inc.

    1-800-RED-CHIP (733-2447)

    or

    407-491-4498

     


    Primary Logo

    View Full Article Hide Full Article
View All Tiziana Life Sciences plc News